通过负载恒定 NKT 配体的 APC 增强术后早期非小细胞肺癌患者的颗粒酶 B 表达 NK 细胞：一项随机 II 期研究结果

NK cells are major effector cells involved in the elimination of early tumors and prevent metastasis. They often have an impaired function in patients with cancer. Preclinical studies have demonstrated NK cell activation as the adjunctive effect of invariant NKT (iNKT) cells. Activation of iNKT cells after administration of the glycolipid ligand -galactosylceramide, loaded with CD1d-expressing human PBMC-derived APCs (APC/Gal), is an attractive cancer therapy to optimize the use of NK cells.

However, the subsets of NK cells that are activated following iNKT cell activation as well as the period of NK cell activation remain unclear. In this study, we report that the granzyme B-expressing NK cell response in postoperative lung cancer patients was enhanced 49 d after administration of APC/Gal in a phase II study.

We found maximum IFN- production on day 49 in 13 out of 27 APC/Gal-treated patients. On day 49, 14 out of 27 patients (51. 9%) had higher IFN- production by iNKT cells (>6-fold higher than the baseline level). This increment significantly correlated with granzyme B-expressing NK cells. Although IFN- production was lower in patients in the nontreated group, we detected maximum IFN- production 12 mo after the resection of lung cancer (9 out of 29 patients [31%]).

These findings suggest that elimination of cancer cells leads to increased NK cell function, which can be further enhanced by APC/Gal therapy.